- ResApp Health (RAP) and Coviu Global have signed an agreement to integrate the ResAppDx-EU acute respiratory diagnostic test on Coviu’s telehealth platform
- The two-year agreement will enable Coviu’s customers to access ResApp’s diagnostic test through Coviu’s platform
- ResApp will receive a licence fee for every test, which will be in the previously-targeted range of $5 and $10
- The ResAppDx Coviu add-on will be available for Coviu’s customers from July 9
- Company shares remain in the grey and are trading for 17.5 cents each
ResApp Health (RAP) and Coviu Global have signed a service agreement to use the ResAppDx-EU acute respiratory diagnostic test on Coviu’s telehealth platform.
The non-exclusive agreement has a two-year term and allows ResApp to provide its diagnostic test to customer within Australia who have Coviu’s web-based platform.
ResApp will receive a licence fee for every test, which will be in the previously targeted range of $5 and $10.
ResAppDx-EU is a smartphone-based acute respiratory disease diagnostic test which is used in telehealth, emergency department and primary care setting. The device is CE Marked in Europe and approved by the Therapeutic Goods Administration in Australia.
“Respiratory symptoms are among the most common reasons for patients to request a telehealth consultation and for the first time clinicians on Coviu’s platform will have an accurate way of assessing those symptoms remotely,” ResApp Managing Director and CEO Tony Keating said.
Coviu’s telehealth platform allows healthcare providers to offer their services directly to patients through a video consultation while incorporating digital assessment tools. Over 22,000 health professionals actively use the Coviu platform.
The ResAppDx Coviu add-on will be available for Coviu’s customers from July 9. Patients with iPhones will be able to access it right away while Android users will need to wait until later this year.
Company shares remain in the grey and are trading for 17.5 cents each at 12:46 pm AEST.